The Acute Spinal Cord Injury drugs in development market research report provides comprehensive information on the therapeutics under development for Acute Spinal Cord Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Acute Spinal Cord Injury. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Acute Spinal Cord Injury and features dormant and discontinued products.
GlobalData tracks 17 drugs in development for Acute Spinal Cord Injury by 17 companies/universities/institutes. The top development phase for Acute Spinal Cord Injury is preclinical with eight drugs in that stage. The Acute Spinal Cord Injury pipeline has 15 drugs in development by companies and two by universities/ institutes. Some of the companies in the Acute Spinal Cord Injury pipeline products market are: NurExone Biologic, Kringle Pharma and S.Biomedics.
The key targets in the Acute Spinal Cord Injury pipeline products market include Gap Junction Alpha 1 Protein (Connexin 43 or Gap Junction 43 Kda Heart Protein or GJA1), Free Radical, and Ephrin Type A Receptor 4 (EPH Like Kinase 8 or Tyrosine Protein Kinase Receptor SEK or Tyrosine Protein Kinase TYRO1 or EPHA4 or EC 2.7.10.1).
The key mechanisms of action in the Acute Spinal Cord Injury pipeline product include Voltage Gated Sodium Channel (SCN) Blocker with one drug in Preclinical. The Acute Spinal Cord Injury pipeline products include six routes of administration with the top ROA being Intrathecal and eight key molecule types in the Acute Spinal Cord Injury pipeline products market including Cell Therapy, and Monoclonal Antibody.
Acute Spinal Cord Injury overview
A spinal cord injury (SCI) is damage to the spinal cord that causes temporary or permanent changes in its function. Symptoms may include loss of muscle function, sensation, or autonomic function in the parts of the body served by the spinal cord below the level of the injury. Acute spinal cord injury (SCI) is due to a traumatic injury that bruises, partially tears, or completely tears the spinal cord.
For a complete picture of Acute Spinal Cord Injury’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
